Evidence map›Paper›PMID 34215673›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022

A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for

Irene Virgolini, Shadfar Bahri, Andreas Kjaer, Henning Grønbæk, Peter Iversen, Esben A Carlsen, Mathias Loft, Ulrich Knigge, Johanna Maffey-Steffan, Christine Powell and 4 more

Open access · hybridAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Malignancy Detection Rates of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Irene VirgoliniDepartment of Nuclear Medicine, University of Innsbruck, Innsbruck, Austria; irene.virgolini@i-med.ac.at.
Shadfar BahriAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Andreas KjaerDepartment of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Henning GrønbækDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Peter IversenDepartment of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark.
Esben A CarlsenDepartment of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Mathias LoftDepartment of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Ulrich KniggeDepartment of Endocrinology PE and Department of Surgery C, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Johanna Maffey-SteffanDepartment of Nuclear Medicine, University of Innsbruck, Innsbruck, Austria.
Christine PowellIpsen Bioscience, Cambridge, Massachusetts.
Colin G MillerBracken Group for Ipsen Bioscience, Newtown, Pennsylvania; and.
Thomas RohbanPartner 4 Health for Ipsen Bioscience, Paris, France.
Sandy McEwanIpsen Bioscience, Cambridge, Massachusetts.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Rigshospitalet · DKAarhus University Hospital · DKUniversität Innsbruck · ATEssen BioScience (United States) · USIpsen (France) · FRUniversity of Copenhagen · DK

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Neuroendocrine TumorsOrganometallic CompoundsGallium RadioisotopesHumansIntestinal NeoplasmsOctreotidePancreatic NeoplasmsPositron Emission Tomography Computed TomographyProspective StudiesRadiopharmaceuticalsReproducibility of ResultsStomach NeoplasmsGallium RadioisotopesOctreotideOrganometallic CompoundsRadiopharmaceuticals68Ga-satoreotide trizoxetandiagnostic imagingneuroendocrine tumorsoptimal dosesomatostatin receptor antagonist

Identifiers

PMID34215673
PMCPMC8978200
OpenAlexW3176734905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.